Anas Daghestani, MD
Internal Medicine · Austin, TXNPI 1366458630
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,794 of the $6,136 with a category attached, or 61.8%. Pfizer accounts for 80.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $4,915 and has fallen 95.8% since, to $206 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $360.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Sanofi Pasteur Inc.$494
- Regeneron Healthcare Solutions, Inc.$246
- AbbVie$205
- ARS Pharmaceuticals Operations, Inc.$84
- Genentech USA, Inc.$78
- plus $63 from 3 others
What the payments were for
- Consulting fees$3,79462%
- Travel & lodging$1,49824%
- Food & beverage$84314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 7 | $4,965 |
| Sanofi Pasteur Inc. | 1 | $494 |
| Regeneron Healthcare Solutions, Inc. | 2 | $246 |
| AbbVie | 2 | $205 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $84 |
| Genentech USA, Inc. | 1 | $78 |
| Myovant Sciences Inc. | 1 | $24 |
| Intuitive Surgical | 1 | $22 |
| Astellas Pharma US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLUZONE HIGH-DOSE$494
- Rinvoq$125
- DUPIXENT$125
How this compares
$6,136 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $26,123 |
| FarxigaDapagliflozin Propanediol | 17 | $13,452 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,055 |
| Omeprazole | 31 | $531 |
| Tamsulosin Hcl | 12 | $428 |
| Testosterone Cypionate | 26 | $408 |
| Atorvastatin Calcium | 63 | $395 |
| Levothyroxine Sodium | 31 | $335 |
| Simvastatin | 17 | $239 |
| Losartan Potassium | 15 | $218 |
| Hydrochlorothiazide | 21 | $187 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 12 | $176 |
| Fluticasone Propionate | 21 | $154 |
| Lovastatin | 11 | $140 |
| Alendronate Sodium | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Austin
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.